Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones

Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) reported 2025 progress and set 2026 targets for its LIBERTY® Endovascular Robotic System. Key 2025 milestones include FDA 510(k) clearance, a Limited Market Release with Emory University Hospital as the first adopter, ACCESS PVI pivotal-trial data showing 100% robotic navigation success and a 92% reduction in radiation, plus 20 patents granted and 52 applications pending. The company plans a Full Market Release in Q2 2026 (aligned with SIR), aims to commercialize against a 2.5 million annual US procedure opportunity, expand global reach, and grow teleintervention and IP monetization efforts.

Positive

• Received FDA 510(k) clearance for LIBERTY
• ACCESS PVI trial: 100% robotic navigation success
• ACCESS PVI trial: 92% reduction in radiation exposure
• Emory University Hospital became the first clinical adopter
• 20 patents granted with 52 patent applications pending
• Planned Full Market Release in Q2 2026 targeting 2.5M US procedures

Negative

• None.

News Market Reaction

+1.91%

1 alert

+1.91% News Effect

On the day this news was published, MBOT gained 1.91%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Target U.S. procedures: 2.5 million procedures annually Robotic navigation success: 100% success Radiation exposure reduction: 92% reduction +5 more

8 metrics

Target U.S. procedures 2.5 million procedures annually Targeted U.S. market for peripheral endovascular procedures

Robotic navigation success 100% success ACCESS PVI pivotal trial robotic navigation outcome

Radiation exposure reduction 92% reduction ACCESS PVI pivotal trial radiation exposure vs. baseline

Granted patents 20 patents Total global patents granted for LIBERTY-related IP

Pending patent applications 52 applications Global patent applications pending approval

Cash and equivalents $6.7 million Cash and cash equivalents as of Sep 30, 2025 (Q3 2025 10-Q)

Marketable securities $73.5 million Marketable securities as of Sep 30, 2025 (Q3 2025 10-Q)

Net loss $3.6 million Q3 2025 net loss (basic and diluted loss per share $0.07)

Market Reality Check

Price: $1.86 Vol: Volume 1,160,842 vs 20-da...

normal vol

$1.86 Last Close

Volume Volume 1,160,842 vs 20-day average 1,387,125 suggests no unusual trading ahead of this release. normal

Technical Shares at $2.09 are trading below the 200-day MA of $2.59, and about 55.25% below the 52-week high of $4.67.

Peers on Argus

MBOT was down 4.57% pre-news, while several peers like AVR, KRMD, INFU, and STXS...

MBOT was down 4.57% pre-news, while several peers like AVR, KRMD, INFU, and STXS showed declines between about 2–4% and NYXH was up 2%, indicating mixed sector action rather than a clearly coordinated move.

Common Catalyst Some peers had their own news (e.g., KRMD earnings, NYXH transparency filing), but no shared robotic-endovascular commercialization theme stands out across headlines.

Historical Context

5 past events · Latest: Nov 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 26	First hospital adoption	Positive	+21.8%	Emory University Hospital became first LIBERTY adopter and partner site.
Nov 05	Limited launch start	Positive	+5.0%	LIBERTY limited U.S. market release with initial commercialization and demand.
Oct 16	Conference debut	Positive	-2.7%	First U.S. medical meeting exhibit for LIBERTY after FDA 510(k) clearance.
Oct 14	Logistics partnership	Positive	-4.3%	U.S. logistics partner secured to support limited release and 2026 launch.
Oct 07	Financing/options	Negative	+0.3%	Exercise of preferred investment options raising funds and issuing new options.

Pattern Detected

Recent news around LIBERTY commercialization and partnerships often produced mixed reactions, with both rallies and selloffs on broadly positive operational updates, and a modest reaction to a sizeable financing/options exercise.

Recent Company History

Over the past few months, MBOT progressed from FDA 510(k) clearance to commercial preparation and initial adoption of the LIBERTY system. Key steps included securing a logistics partner on Oct 14, 2025, debuting LIBERTY at a major conference on Oct 16, 2025, commencing a U.S. limited market release on Nov 5, 2025, and announcing Emory University Hospital as the first adopter on Nov 26, 2025. A financing/options transaction on Oct 7, 2025 modestly moved the stock. Today’s roadmap and milestone update builds directly on these commercialization and adoption milestones.

Regulatory & Risk Context

Active S-3 Shelf · $25,000.00

Shelf Active

Active S-3 Shelf Registration 2025-10-28

$25,000.00 registered capacity

An active Form S-3 shelf, amended on Oct 28, 2025, is in place, with Amendment No. 1 mainly updating Rule 473(b) language and expense details. It has seen 2 recent 424B3 usages, indicating established infrastructure for potential securities-related activity under this registration.

Market Pulse Summary

This announcement outlines MBOT’s transition from a limited market release of LIBERTY to a planned f...

Analysis

This announcement outlines MBOT’s transition from a limited market release of LIBERTY to a planned full market release in Q2 2026, targeting a U.S. market of 2.5 million peripheral endovascular procedures annually. It builds on 510(k) clearance, first-hospital adoption, strong ACCESS PVI data (100% navigation success, 92% radiation reduction), and an expanding IP portfolio. Against prior financings and an active S-3 shelf, investors may track commercialization pace, additional hospital adoptions, and progress in teleintervention and autonomous robotics collaborations.

Key Terms

510(k) clearance, peripheral endovascular procedures, interventional radiology, Teleintervention, +3 more

7 terms

510(k) clearance regulatory

"obtaining FDA 510(k) clearance for LIBERTY, the first single-use..."

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

peripheral endovascular procedures medical

"robotic system for peripheral endovascular procedures. The Company initiated..."

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

interventional radiology medical

"Program in interventional radiology to enhance the growing and evolving..."

Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.

Teleintervention medical

"Advanced Teleintervention™ collaboration with Corewell Health™ as LIBERTY successfully..."

Teleintervention is the delivery of medical treatments, therapies, or clinical support remotely using video calls, apps, or other digital tools instead of in-person visits. For investors it signals services that can reach more patients at lower cost, scale quickly like a software product, and depend on reimbursement rules and privacy safeguards—factors that affect revenue potential, regulatory risk, and adoption rates. Think of it as a remote coach or therapist using technology to provide care.

autonomous robotics technical

"collaborations with leading institutions in the areas of teleintervention and autonomous robotics..."

Autonomous robotics are machines and systems that can perform tasks, make decisions, and adapt to changing conditions without continuous human control — like a self-driving vehicle for manufacturing, delivery, inspection, or service work. Investors care because these robots can lower labor costs, increase speed and consistency, open new markets and revenue streams, and change competitive dynamics, while also carrying adoption, regulation, maintenance and integration risks that affect returns.

limited market release technical

"initiated its limited market release, quickly achieving its first customer..."

A limited market release is a staged launch of a product or service into a small group of customers, a specific region, or select sales channels before a full nationwide or global rollout. For investors it signals an early test of demand, production and distribution systems—like a pilot episode or a test drive—providing advance evidence about revenue potential, customer acceptance and the risks or costs of scaling up.

full market release technical

"Prepares for Full Market Release (FMR) in Q2..."

A full market release is the simultaneous public distribution of material company information through official channels so all investors and market participants receive the same news at the same time. It matters because it promotes fair and orderly trading—reducing the chance that a few people trade on secret information—and can trigger immediate price moves as everyone reassesses a stock based on the newly shared facts, like broadcasting an announcement to an entire stadium at once.

AI-generated analysis. Not financial advice.

Limited Market Release (LMR) of the LIBERTY^® System is on Schedule

Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2

HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, including several pivotal achievements such as obtaining FDA 510(k) clearance for LIBERTY, the first single-use, remotely operated robotic system for peripheral endovascular procedures. The Company initiated its limited market release, quickly achieving its first customer to adopt LIBERTY for patient care. The Company is positioning itself to leverage this momentum and commercialize LIBERTY across a targeted U.S. market of 2.5 million peripheral endovascular procedures annually. This progress enables the Company to pursue and strive for the 2026 anticipated milestones listed below.

Key 2025 Operational and Business Achievements

• Received FDA clearance.
• Launched the Limited Market Release of LIBERTY, strategically introducing LIBERTY into select high procedure volume regions, leveraging early demand to accelerate adoption.
• Emory University Hospital, a nationally recognized academic medical center in Atlanta, became the first hospital to adopt the LIBERTY system shortly after the company commenced its commercialization. The Company is collaborating with Emory to establish an Endovascular Robotics Program in interventional radiology to enhance the growing and evolving specialty field.
• Established an experienced commercial leadership team, including in key sales and marketing roles, to strengthen the Company’s launch readiness plans.  
• Expanded the cross-functional team to support launch readiness of LIBERTY.
• Presented data from the ACCESS PVI pivotal trial at the Society of Interventional Radiology (SIR) annual meeting, highlighting 100% robotic navigation success, a 92% reduction in radiation exposure and no adverse device events reported.
• Attended CIO, the first scientific conference since receiving FDA clearance, with overwhelming positive feedback from attendees.
• Partnered with third-party manufacturers and logistics organizations to ensure greater efficiencies and meet expected customer demand.
• Advanced Teleintervention™ collaboration with Corewell Health™ as LIBERTY successfully performed simulated vascular navigation across two sites within the Corewell Health™ system, located five miles apart.
• Expanded its IP Portfolio with Global Patent Allowances in the U.S., Japan, Europe and Israel, resulting in a total of 20 patents granted and 52 patent applications pending approval.
• Added as a member of the Russell Microcap^® Index, which Microbot believes reflects its continued strong execution and progress.
• Bolstered the balance sheet, which also included a non-dilutive grant, to further strengthen the company’s commercial capabilities.

Anticipated 2026 Operational and Commercial Milestones

• Commence the Full Market Release (FMR) of the LIBERTY System in Q2 2026, in conjunction with the Society of Interventional Radiology (SIR) conference.
• Grow customer base by attracting early adopters and securing new hospitals with medium-to-high volume target procedures.
• Validate the LIBERTY System’s significant market opportunity, with the expansion of the types of procedures that are being performed as well as the end user call point to include interventional radiologists, vascular surgeons, and interventional cardiologists.
• Establish commercial and operational infrastructure to support expansion into markets outside the USA, either under FDA Clearance or other regional and local regulatory approvals.
• Enhance the Company’s core capabilities by filling cross-functional roles with the right talent to support execution and future growth.
• Maintain a strong presence at key medical societies and conferences, including the Society of Interventional Oncology (SIO) and International Symposium on Endovascular Therapy (ISET) in February, Society of Interventional Radiology (SIR) in April, Global Embolization Symposium and Technologies (GEST) in May and Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in September.
• Continue to establish pipelines to allow future growth to other interventional spaces (cardiology, neurovascular) and increase the utilization opportunity within the peripheral space.
• Continue collaborations with leading institutions in the areas of teleintervention and autonomous robotics and explore additional opportunities to leverage the innovative LIBERTY technology.
• Expand and protect the Company’s global IP portfolio, which creates barriers to entry, and allows the Company to monetize its innovative technology.
• Leverage the strong balance sheet to fully execute its near and medium-term commercial strategy in the U.S. and globally, and to support its product development pipeline.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

What regulatory milestone did Microbot Medical (MBOT) achieve for LIBERTY in 2025?

Microbot Medical received FDA 510(k) clearance for the LIBERTY system in 2025.

When is Microbot Medical (MBOT) planning the Full Market Release of LIBERTY?

The company plans to commence the Full Market Release in Q2 2026, aligned with the SIR conference.

What were the ACCESS PVI trial results announced by Microbot Medical (MBOT)?

ACCESS PVI data reported 100% robotic navigation success, a 92% reduction in radiation, and no adverse device events.

Which hospital was the first to adopt LIBERTY for patient care?

Emory University Hospital was the first hospital to adopt the LIBERTY system.

How large is the target U.S. market Microbot Medical (MBOT) cites for LIBERTY?

The company cites a targeted U.S. market of 2.5 million peripheral endovascular procedures annually.

What intellectual property position does Microbot Medical (MBOT) report?

Microbot reports 20 patents granted and 52 patent applications pending across multiple jurisdictions.